Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.36 USD | +2.61% |
|
+3.51% | +1.29% |
Jun. 13 | Vyne Therapeutics Announces Dosing of First Participants in Phase 1A Trial of Novel Bd2-Selective Bet Inhibitor Vyn202 | CI |
Jun. 07 | Top Premarket Gainers | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.29% | 34.29M | |
+51.82% | 797B | |
+39.95% | 628B | |
+16.95% | 323B | |
+9.49% | 300B | |
+16.68% | 244B | |
+0.49% | 223B | |
+9.79% | 214B | |
+5.30% | 163B | |
-6.29% | 153B |
- Stock Market
- Equities
- VYNE Stock
- News VYNE Therapeutics Inc.
- Menlo Therapeutics Inc. Announces Board Changes